Explore Muscle Protein, Muscular Dystrophies and more!

Explore related topics

Read about four potential serum biomarkers of disease progression and clinical outcomes in three types of muscular dystrophies.

Read about four potential serum biomarkers of disease progression and clinical outcomes in three types of muscular dystrophies.

Systemic sclerosis (SSc) is a systemic connective tissue disease. Characteristics of systemic sclerosis include essential vasomotor disturbances; fibrosis; subsequent atrophy of the skin, subcutaneous tissue, muscles, and internal organs (eg, alimentary tract, lungs, heart, kidney, CNS); and immunologic disturbances accompany these findings.

SSc Patients With Gastrointestinal Symptoms Benefit From IV Immunoglobulin Treatment

Learn How to Become a Forensic Chemist, their Salary, Skills, Responsibilities, and Education

For children, adults with muscular dystrophy, research at KU holds new hope - Kara Jacobs sits on Tuesday, April 21, near leg braces her 7-year-old son, Zane Jacobs, uses in their home in Eudora, Kan. Zane has Duchenne muscular dystrophy, which causes muscle weakness and loss of muscle tissue that leads to progressively worsening disability. Zane is part of a double blind University of Kansas clinical trial to treat Duchenne muscular dystrophy.

For children, adults with muscular dystrophy, research at KU holds new hope

Muscular Dystrophy Ambassador

Muscular Dystrophy Association and Catabasis Pharmaceuticals Collaborate on Clinical Study

Interim results from the Phase 1/2 trial clinical trial investigating CAP-1002 as a treatment for heart disease associated with Duchenne muscular dystrophy (DMD) are being presented today at the 20…

6-Month Results of Study into Stem Cell Therapy for Heart Disease in Duchenne Patients Part of PPMD Conference

Interim results from the Phase 1/2 trial clinical trial investigating CAP-1002 as a treatment for heart disease associated with Duchenne muscular dystrophy (DMD) are being presented today at the 20…

The latest results of the Phase 3 clinical trial for PTC Therapeutics’ candidate Translarna (ataluren) for the treatment of nonsense mutation Duchenne muscular dystrophy (nmDMD) showed that it can …

Translarna Beneficial for Patients in Transitional Stage of Nonsense Mutation Duchenne MD, Study Finds

The latest results of the Phase 3 clinical trial for PTC Therapeutics’ candidate Translarna (ataluren) for the treatment of nonsense mutation Duchenne muscular dystrophy (nmDMD) showed that it can …

Phase 3 Trial Results Look Promising for Potential Duchenne MD Therapy Deflazacort #MuscularDystrophyNews

Phase 3 Trial Results Look Promising for Potential Duchenne MD Therapy Deflazacort

Phase 3 Trial Results Look Promising for Potential Duchenne MD Therapy Deflazacort #MuscularDystrophyNews

Study of Potential Therapy for Congenital Muscular Dystrophy Gets Boost from FDA #MuscularDystrophyNews

Study of Potential Therapy for Congenital Muscular Dystrophy Gets Boost from FDA

Study of Potential Therapy for Congenital Muscular Dystrophy Gets Boost from FDA #MuscularDystrophyNews

Researchers say it is important to carefully assess the timing of the start of corticosteroid treatment for Duchenne muscular dystrophy (DMD) in children and its potential association with disease …

Earlier Start of Corticosteroids in DMD Linked to Earlier Heart Disease Onset, Study Suggests

Researchers say it is important to carefully assess the timing of the start of corticosteroid treatment for Duchenne muscular dystrophy (DMD) in children and its potential association with disease …

<span class="entry-title">First DMD Patients Enroll in Phase 2 Study of FibroGen’s FG-3019</span><span class="entry-subtitle">Potential fibrotic disease therapy expands to non-ambulatory Duchenne muscular dystrophy patients</span>

First DMD Patients Enroll in Phase 2 Study of FibroGen’s FG-3019

read about FibroGen enrolling the first two patients in a new Phase 2 trial to investigate its compound in Duchenne muscular dystrophy patients.

Pinterest
Search